pramipexole

Adjunctive therapy • Brands: Mirapex

Last reviewed: 2025-12-30

General information

Class: Adjunctive therapy
Common US brands: Mirapex
Typical dose range: RLS: start 0.125 mg once daily 2 to 3 hours before bedtime; dose may be increased every 4 to 7 days based on response and tolerability (label).
Therapeutic drug monitoring not routinely recommended.
Last reviewed: 2025-12-30

Dosing & forms

Forms/strengths: Tablets: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg (label).
Frequency: RLS: start 0.125 mg once daily 2 to 3 hours before bedtime; dose may be increased every 4 to 7 days based on response and tolerability (label).
Typical range: RLS: start 0.125 mg once daily 2 to 3 hours before bedtime; dose may be increased every 4 to 7 days based on response and tolerability (label).

Mechanism (brief)

Non-ergoline dopamine agonist (D2/D3-preferring) indicated for Parkinson’s disease and moderate-to-severe primary restless legs syndrome; largely renally eliminated as unchanged drug with clinically important somnolence, impulse- control, hallucination/psychosis, and RLS augmentation considerations.

Metabolism & Half‑life

Metabolism: Negligible metabolism (<10%); not CYP-mediated (label).
Half‑life: Single-dose range 8–12 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

View labelExact

Monitoring highlights

Somnolence and sudden sleep onset monitoring; driving safety review (label).
Orthostatic blood pressure and dizziness/falls risk monitoring (label/clinical).
Hallucinations/psychosis and mood destabilization monitoring, especially in serious mental illness (label/clinical).
Impulse-control symptom monitoring (new compulsive behaviors) (label/clinical).
RLS symptom timing tracking to detect augmentation (earlier onset, increased severity, spread) (guideline/clinical).
Renal function review and renal-dose adjustment as needed (label).

Sources

Pramipexole dihydrochloride tablets prescribing information — DailyMed (2025)
Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2025)
The Management of Restless Legs Syndrome: An Updated Algorithm — Mayo Clinic Proceedings (2021)
Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood — Sleep Medicine (2011)

Dosing & forms

Forms/strengths: Tablets: 0.125 mg, 0.25 mg, 0.5 mg, 1 mg, and 1.5 mg (label).

Frequency: RLS: start 0.125 mg once daily 2 to 3 hours before bedtime; dose may be increased every 4 to 7 days based on response and tolerability (label).

Typical range: RLS: start 0.125 mg once daily 2 to 3 hours before bedtime; dose may be increased every 4 to 7 days based on response and tolerability (label).

Mechanism (brief)

Monitoring highlights

Somnolence and sudden sleep onset monitoring; driving safety review (label).

Orthostatic blood pressure and dizziness/falls risk monitoring (label/clinical).

Hallucinations/psychosis and mood destabilization monitoring, especially in serious mental illness (label/clinical).

Impulse-control symptom monitoring (new compulsive behaviors) (label/clinical).

RLS symptom timing tracking to detect augmentation (earlier onset, increased severity, spread) (guideline/clinical).

Renal function review and renal-dose adjustment as needed (label).